Bayer contributes to Healthy China 2030 - (Global Times via NewsPoints Desk)

  • Bayer recently opened an expansion of its pharmaceutical products supply site in Beijing, Global Times reported Thursday.

  • The expansion at the facility, at a cost of 100 million euros will allow Bayer to double production capacity, including products such as Adalat, Bayaspirin and Glucobay.

  • The investment comes after the World Health Organization in 2013 called on countries and regions to reduce premature deaths from non-communicable diseases by 25 percent by 2025.

  • Meanwhile, China set a target of a 30-percent decline in premature death from chronic diseases by 2030.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles